A Phase II Study Evaluating the Safety and Efficacy of the Combination of Zanubrutinib Plus Lisocabtagene Maraleucel for Richter's Syndrome
Latest Information Update: 10 Apr 2025
At a glance
- Drugs Lisocabtagene-maraleucel (Primary) ; Zanubrutinib (Primary) ; Cyclophosphamide; Fludarabine
- Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Richter's syndrome
- Focus Therapeutic Use
Most Recent Events
- 04 Feb 2025 Planned End Date changed from 31 Dec 2025 to 31 Dec 2026.
- 04 Feb 2025 Planned primary completion date changed from 31 Dec 2025 to 31 Dec 2026.
- 12 Jun 2023 Status changed from not yet recruiting to recruiting.